AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method for the purification of a cytochrome P450, wherein said method comprises:

(a) expressing in a host cell culture a cytochrome P450 molecule;

(b) recovering said cells from said culture and suspending said cells in a salt buffer having a salt concentration of from 200 to 1000 mM and a conductivity of from 12 to 110 mS/cm;

(c) lysing said cells and removing cell debris to provide a high-salt lysate;

(d) adding to said lysate a detergent to provide a high-salt-detergent lysate; and

(e) recovering said P450 from said lysate;

provided that when said salt buffer has a concentration of from 200 to 1000mM, the P450 is not a human 2C9 P450 having position 220 substituted by proline.

2. (Currently Amended) The method of claim 1 wherein the salt buffer has a salt concentration of about 500 mM ± 50 mM ~~from 200 to 1000 mM~~.

3. (Previously Presented)The method of claim 1 wherein the detergent is added at 0.015 to 1.2% v/v.

4. (Currently Amended) The method of claim 1 wherein step (e) is performed by:

(e(i)) binding said P450 to an affinity support;

(e(ii)) rinsing said support in a high-salt-detergent wash having a salt concentration of from 200 to 1000 mM and a conductivity of from 12 to 110 mS/cm;

(e(iii)) removing said P450 in a high-salt-detergent buffer having a salt concentration of from 200 to 1000 mM and a conductivity of from 12 to 110 mS/cm to provide a P450-high-salt-detergent preparation; and

(f) rapidly desalting the preparation to provide a P450-low-salt preparation.

5. (Original) The method of claim 4 wherein step (f) is performed by removing salt from said preparation by size-exclusion chromatography.

6. (Previously Presented) The method of claim 1 wherein the P450 carries a polyhistidine tag.

7. (Previously Presented) The method of claim 1 wherein the P450 is a member of the CYP1, 2, 3 or 4 family.

8. (Original) The method of claim 7 wherein the P450 is a CYP2 family member.

9. (Original) The method of claim 8 wherein the P450 is 2C9 or 2C19.

10. (Currently Amended) The method of claim 1 wherein the P450 in its native form comprises an N-terminal membrane inserting element and wherein said inserting element is deleted~~a deletion in its N-terminal membrane inserting element~~.

11. (Currently Amended) The method of claim 10 wherein the N-terminal sequence of said P450 comprises, in place of the N-terminal membrane inserting element, a sequence MAKKTSSKGR (SEQ ID NO:10) or MAYGTHSHGLFKK (SEQ ID NO:11).

12. (Original) The method of claim 11 wherein said P450 is of SEQ ID NO:2, 4, 6 or 8.

13. (Currently Amended) The method of claim 1 wherein said P450 is selected from the group of P450 2C9, P450 2C19, P450 2C19-1B, P450 2D6 and P450 3A4 wherein said method ~~which~~ further comprising ~~comprises~~ crystallizing the P450.

Claims 14-20. (Canceled)

21. (New) The method of claim 2 wherein said buffer has a conductivity of from 25 to 35 mS/cm.

22. (New) The method of claim 1 wherein the buffer comprises a salt selected from the group consisting of an alkali metal, alkaline earth metal, ammonium, ferric, ferrous and transition metal salt of a halide, acetate, formate, nitrate, sulfate, tartrate, citrate or phosphate.

23. (New) The method of claim 21 wherein the salt is selected from the group

consisting of sodium fluoride, potassium fluoride, ammonium fluoride, ammonium chloride, lithium chloride, magnesium chloride, potassium chloride, sodium chloride, potassium bromide, ammonium nitrate, lithium nitrate, potassium nitrate, sodium nitrate, ammonium sulfate, potassium sulfate, lithium sulfate, sodium sulfate, potassium dihydrogen phosphate, ferric chloride, calcium chloride, magnesium nitrate, magnesium sulfate, sodium dihydrogen phosphate, di-sodium hydrogen phosphate, di-potassium hydrogen phosphate, ammonium dihydrogen phosphate, di-ammonium hydrogen phosphate, nickel chloride, and ammonium iodide.